Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

Ain Shams University

Status: Not yet enrolling

Conditions: Subclinical Right Ventricular Systolic Dysfunction; Psoriatic Arthritis (PsA)

Study type: Observational

Funder types: Other

Identifiers

NCT07046312

MD13/2025

Details and patient eligibility

About

The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography

Full description

Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography.

To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.

Enrollment: 60 estimated patients

Sex: All

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Psoriatic arthritis patients according to CASPAR criteria
• Psoriatic arthritis patients without overt cardiovascular symptoms
• Patients with age between 20 to 50 years of age

Exclusion criteria

• Other systemic autoimmune diseases
• Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
• Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
• Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
• Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.

Trial design

60 participants in 2 patient groups

Control

Description:

30 control group matched as regards BMI, age and sex will be subjected to transthoracic echo and measuring serum endostatin level.

Cases of Psoriatic arthritis patients

Description:

30 PsA patients will be subjected to transthoracic echo, measuring serum endostatin level and modified composite psoriatic disease activity index